Cytogenetic prognostication within medulloblastoma subgroups.
暂无分享,去创建一个
Toshihiro Kumabe | Amar Gajjar | Andrey Korshunov | Nada Jabado | David T. W. Jones | Uri Tabori | Boleslaw Lach | Xin Wang | Olivier Delattre | Franck Bourdeaut | Teiji Tominaga | Eric Bouffet | Stefan Rutkowski | László Bognár | Seung-Ki Kim | Simon Bailey | Anne Jouvet | Ulrich Schüller | Marcel Kool | Nalin Gupta | Giuseppe Cinalli | Vijay Ramaswamy | Maryam Fouladi | Livia Garzia | Shenandoah Robinson | S. Scherer | J. Olson | Erwin G. Van Meir | M. Kool | L. Liau | J. Mora | P. Northcott | S. Pfister | Shin Jung | J. Rutka | C. Hawkins | S. Pomeroy | O. Delattre | I. Pollack | U. Schüller | Yoon-Jae Cho | A. Jouvet | A. Korshunov | K. Muraszko | T. Tominaga | C. Lavarino | R. Wechsler-Reya | W. Weiss | P. French | J. Kros | A. Morrissy | A. Fontebasso | S. Albrecht | P. Hauser | M. Garami | A. Klekner | L. Bognár | M. Remke | Michael D. Taylor | N. Jabado | D. Malkin | C. Eberhart | W. Grajkowska | R. Packer | A. Dubuc | Xiaochong Wu | S. Robinson | S. Rutkowski | R. Thompson | S. Mack | A. Gajjar | J. Phillips | F. Bourdeaut | M. Zollo | L. Garzia | D. Shih | F. Cavalli | V. Ramaswamy | Xin Wang | J. Peacock | Adi Rolider | C. Faria | T. Kumabe | L. Massimi | K. Zitterbart | K. Wang | B. Cho | S. Bailey | J. Lindsey | S. Clifford | M. K. Cooper | U. Tabori | E. Bouffet | Seung-Ki Kim | C. de Torres | E. Michiels | Xing Fan | M. Fouladi | Pasqualino de Antonellis | Yuan Yao | M. Perek-Polnik | F. Doz | M. Fèvre-Montange | Nanne K. Kloosterhof | L. Křen | B. Lach | N. Gupta | J. Leonard | J. Rubin | G. Cinalli | A. Saad | R. Vibhakar | C. Di Rocco | Marc Remke | Betty Luu | Yoon-Jae Cho | Marta Perek-Polnik | Jaume Mora | Michelle Fèvre-Montange | Karel Zitterbart | Leos Kren | Almos Klekner | Peter Hauser | Shin Jung | Luca Massimi | Rajeev Vibhakar | Xing Fan | David Malkin | Michael D. Taylor | Stephen W. Scherer | James T. Rutka | Concezio Di Rocco | Xiaochong Wu | Adi Rolider | Pasqualino De Antonellis | Massimo Zollo | Kyu-Chang Wang | Byung-Kyu Cho | Roger J. Packer | Charles G. Eberhart | Miklós Garami | David J.H. Shih | Paul A. Northcott | Yuan Yao | Adrian M. Dubuc | John Peacock | Stephen C. Mack | A. Sorana Morrissy | Florence M.G. Cavalli | David T.W. Jones | Claudia C. Faria | Young Shin Ra | Jennifer A. Chan | Ali G. Saad | Linda M. Liau | Steffen Albrecht | Adam Fontebasso | Michael K. Cooper | Reid C. Thompson | Janet C. Lindsey | Erna M.C. Michiels | Joanna J. Phillips | Karin M. Muraszko | Robert J. Wechsler-Reya | Ian F. Pollack | William A. Weiss | Ji-Yeoun Lee | Jeffrey R. Leonard | Joshua B. Rubin | Carmen de Torres | Cinzia Lavarino | James M. Olson | Scott L. Pomeroy | Pim J. French | Nanne K. Kloosterhof | Johan M. Kros | Erwin G. Van Meir | Steven C. Clifford | François F. Doz | Cynthia E. Hawkins | Wieslawa A. Grajkowska | Stefan M. Pfister | J. Chan | Ji-Yeoun Lee | B. Luu | Young Shin Ra | M. Perek‐polnik | Á. Klekner | L. Bognár | N. Gupta | Seung-Ki Kim | N. Gupta | J. Leonard | Rajeev Vibhakar | Yuan Yao
[1] D. Ellison,et al. Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.
[2] Roger E. Taylor,et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Paul A. Northcott,et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.
[4] P. Northcott,et al. The Genetics of Pediatric Brain Tumors , 2010, Current neurology and neuroscience reports.
[5] David T. W. Jones,et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma , 2012, Acta Neuropathologica.
[6] W. Mason,et al. Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. , 2011, Neuro-Oncology.
[7] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[8] P. Lichter,et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Biegel,et al. Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.
[10] Axel Benner,et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Björk-Eriksson,et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Trojanowski,et al. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. , 2000, Klinische Padiatrie.
[13] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[14] D. Ellison,et al. Rapid Diagnosis of Medulloblastoma Molecular Subgroups , 2011, Clinical Cancer Research.
[15] J. Morgan. HOSPITAL FOR SICK CHILDREN. , 1884 .
[16] O. Delattre,et al. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. , 2013, Cancer genetics.
[17] Stefan M. Pfister,et al. The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.
[18] P. Northcott,et al. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. , 2011, Cancer genetics.
[19] S. Pomeroy,et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Arceci. Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification , 2010 .
[21] Scott L. Pomeroy,et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.
[22] Arie Perry,et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.
[23] Paul A. Northcott,et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies , 2013, Acta Neuropathologica.
[24] D. Grzybicki,et al. Subtypes of medulloblastoma have distinct developmental origins , 2012 .
[25] R. McLendon,et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. , 2002, Archives of pathology & laboratory medicine.
[26] S. Joos,et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Scherer,et al. Subgroup-specific alternative splicing in medulloblastoma , 2012, Acta Neuropathologica.
[28] J. Uhm. Medulloblastoma Comprises Four Distinct Molecular Variants , 2011 .
[29] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] K. Evankovich,et al. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. , 2010, Neuro-oncology.
[31] S. Pomeroy,et al. Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma , 2007, Clinical Cancer Research.
[32] P. Northcott,et al. Molecular subgroups of medulloblastoma , 2012, Expert review of neurotherapeutics.
[33] O. Delattre,et al. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. , 2012, Neuro-oncology.
[34] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[35] C. Dang,et al. Histopathological and Molecular Prognostic Markers in Medulloblastoma: c‐myc, N‐myc, TrkC, and Anaplasia , 2004, Journal of neuropathology and experimental neurology.
[36] Axel Benner,et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] David T. W. Jones,et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. , 2013, The Lancet. Oncology.
[38] Axel Benner,et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Pfister,et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma , 2011, Acta Neuropathologica.
[40] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[41] D. Ellison,et al. Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: Requirements for the validation of potential prognostic biomarkers , 2009, Cell Cycle.
[42] P. Stankiewicz,et al. Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement. , 2012, Neuro-oncology.
[43] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[44] C. Hawkins,et al. Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma , 2009, Current oncology.
[45] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[46] R. McLendon,et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas , 2005, Journal of Neuro-Oncology.
[47] D. Ellison,et al. Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.
[48] R. Arceci. Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations , 2010 .
[49] R. Perry,et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. , 1995, British Journal of Cancer.
[50] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[51] S. Croul,et al. Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. McLendon,et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. , 2010, Cancer research.
[53] J. Crolla,et al. Clinical and molecular stratification of disease risk in medulloblastoma , 2001, British Journal of Cancer.
[54] David T. W. Jones,et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.
[55] V. P. Collins,et al. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma , 2011, Neuro-Oncology.
[56] P. Northcott,et al. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. , 2010, Neurosurgical focus.
[57] R H Perry,et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.
[58] J. Mesirov,et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[60] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[62] M. Kool,et al. Molecular diagnostics of CNS embryonal tumors , 2010, Acta Neuropathologica.
[63] Paul A. Northcott,et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct , 2011, Acta Neuropathologica.
[64] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.